Blocks.diy raises $10M to let teams build custom AI tools in minutes
Marking monday.com's first startup investment, the funding supports Blocks.diy in helping teams build and adopt AI tools that boost workplace efficiency
Founded less than a year ago by two monday.com alumni, Blocks.diy is the first to combine an AI app builder with smart agents that multiply productivity. These agents extract, analyze, and coordinate data across systems automatically, while professionals guide their behavior. The platform integrates with systems like HubSpot CRM, LinkedIn, and monday.com boards, shifting work tools from passive to active, intelligent processes.
Blocks.diy also offers a marketplace of expert-built templates, ready to use or customize. The platform is already used by hospitals, venture funds, and tech operations teams and meets SOC 2, ISO 27001, and GDPR standards, ensuring customized tools meet regulatory standards.
"During my seven years leading product development at monday.com, I saw how no-code tools improved efficiency," explains
"Working with Michal and Tal at monday.com, we saw their strategic and technological strengths," notes
"Michal and Tal recognized that the power of AI is making it accessible to every employee," says
About Blocks.diy:
Founded in 2025 by monday.com alumni, Blocks.diy is an AI-native platform that lets organizations build intelligent work tools and AI agents through simple conversation. It integrates with existing systems while professionals retain control, enabling employees at any level to create solutions that drive productivity and results.
Media Contact
ReBlonde for Blocks.diy
[email protected]
Photo - https://mma.prnewswire.com/media/2770173/Blocks_diy_team.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/blocksdiy-raises-10m-to-let-teams-build-custom-ai-tools-in-minutes-302552642.html
SOURCE Blocks.diy
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C
- Sotheby's International Realty Expands into Panama
- 357-Year-Old Chinese Medicine Brand Celebrates Health, Heritage And Reunion In New York Times Square
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share